Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$GNLX Possible Breakout! announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor
Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.
The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.